| ［1］ Benoit L, Arnould L, Cheynel N, et al. Malignant extraovarian endometriosis: a review［J］. Eur J Surg Oncol, 2006,32(1):6-11.［2］ Wang S, Qiu L, Lang JH, et al. Clinical analysis of ovarian epithelial carcinoma with coexisting pelvic endometriosis［J］. Am J Obstet Gynecol, 2013,208(5):413.e1-5. ［3］ Modesitt SC, Tortolero-Luna G, Robinson JB, et al. Ovarian and extraovarian endometriosis-associated cancer［J］. Obstet Gynecol, 2002,100(4):788-795.［4］ 冷金花, 郎景和. 子宫内膜异位症恶变的研究现状［J］. 实用肿瘤杂志, 2006,(6):494-495.［5］ Munksgaard PS, Blaakaer J. The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations［J］. Gynecol Oncol, 2012,124(1):164-169.［6］ Varma R, Rollason T, Gupta JK, et al. Endometriosis and the neoplastic process［J］. Reproduction (Cambridge, England), 2004,127(3):293-304.［7］ Mills S. Sternberg's Diagnostic Surgical Pathology［M］. 5th ed. Philadelphia: Lippincott William & Wilkins, 2010: chapters 44, 54, 58.［8］ Nomoto K, Hori T, Kiya C, et al. Endometrioid adenocarcinoma of the vagina with a microglandular pattern arising from endometriosis after hysterectomy［J］. Pathol Int, 2010,60(9):636-641.［9］ Karanjgaokar VC, Murphy DJ, Samra JS, et al. Malignant transformation of residual endometriosis after hysterectomy: a case series［J］. Fertil Steril, 2009,92(6):2037.e19-21.［10］ Magtibay PM, Heppell J, Leslie KO. Endometriosis-associated invasive adenocarcinoma involving the rectum in a postmenopausal female: report of a case［J］. Dis Colon Rectum, 2001,44(10):1530-1533.［11］ Soliman NF, Hillard TC. Hormone replacement therapy in women with past history of endometriosis［J］. Climacteric, 2006,9(5):325-335.［12］ Zanetta GM, Webb MJ, Li H, et al. Hyperestrogenism: a relevant risk factor for the development of cancer from endometriosis［J］. Gynecol Oncol, 2000,79(1):18-22.［13］ Haney AF, Wild RA. Options for hormone therapy in women who have had a hysterectomy［J］. Menopause (New York, N.Y.), 2007,14(3 Pt 2):592-597.［14］ Cumiskey J, Whyte P, Kelehan P, et al. A detailed morphologic and immunohistochemical comparison of pre- and postmenopausal endometriosis［J］. J Clin Pathol, 2008,61(4):455-459.［15］ Guan B, Mao TL, Panuganti PK, et al. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma［J］. Am J Surg Pathol, 2011,35(5):625-632.［16］ Mandai M, Yamaguchi K, Matsumura N, et al. Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management［J］. Int J Clin Oncol, 2009,14(5):383-391.［17］ Xu B, Hamada S, Kusuki I, et al. Possible involvement of loss of heterozygosity in malignant transformation of ovarian endometriosis［J］. Gynecol Oncol, 2011,120(2):239-246.［18］ Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas［J］. N Engl J Med Overseas Ed, 2010,363(16):1532-1543.［19］ Yamamoto S, Tsuda H, Takano M, et al. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations［J］. Modern Pathol, 2012,25(4):615-624.［20］ Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?［J］. Lancet, 2001,357(9255):539-545.［21］ Nezhat F, Datta MS, Hanson V, et al. The relationship of endometriosis and ovarian malignancy: a review［J］. Fertil Steril, 2008,90(5):1559-1570.［22］ Yamaguchi K, Mandai M, Toyokuni S, et al. Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the iron-induced persistent oxidative stress［J］. Clin Cancer Res, 2008,14(1):32-40.［23］ Kobayashi H, Kajihara H, Yamada Y, et al. Risk of carcinoma in women with ovarian endometrioma［J］. Front Biosci (Elite Ed), 2011,3:529-539.［24］ Van Gorp T, Amant F, Neven P, et al. Endometriosis and the development of malignant tumours of the pelvis:a review of literature［J］. Best Pract Res Clin Obstet Gynaecol, 2004,18(2):349-371.（2013-10-21收稿 2014-07-10修回） |
